Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925956 | 0.86 | ALDH1A1 (0.63) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL9476484 | 0.85 | GRM2 (0.53) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL9476208 | 0.85 | HTT (0.58) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL4923637 | 0.84 | ALDH1A1 (0.69) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL15313079 | 0.83 | ALDH1A1 (0.63) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL15313075 | 0.82 | CYBB (0.69) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL9477387 | 0.82 | HTT (0.51) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL4928309 | 0.81 | ALDH1A1 (0.52) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL9476934 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1PKMTSHRKDM4E | |
| SCHEMBL9475889 | 0.81 | ALDH1A1 (0.61) | ALDH1A1PKMTSHRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1756113-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | Vasopharm Biotech GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | ALDH1A1 284/4885NPSR1 932/4885PKM 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.